HPLC-MS is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-12-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Investigational status in most countries |
| Sports status | Prohibited by WADA | Classified as non-approved or metabolic modulator |
| Common analytical method | LC-MS/MS | Used for trace detection in biological samples |
| Typical test matrices | Urine and blood | Sample choice depends on testing program |
| Human trial data | None published | Effects and safety are not established |
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Raman, when coupled with microfluidic devices, can also monitor fluid mixing and trapping of liquids and can also detect solid and gas phases within microfluidic platforms, an ability that is applicable to the study of gas-liquid solubility. Raman spectroscopy in microfluidic devices is applied and detected using either integrated fiberoptics within a microfluidic chip or by placing the device on a Raman microscope. Furthermore, some microfluidic systems utilize metallic colloid or nanoparticles within solution to capitalize on surface-enhanced Raman spectroscopy (SERS). SERS can improve Raman scattering by up to a factor of 1011 by forming charge-transfer complexes on the surfaces. It follows that these devices are commonly fabricated out of nanoporous polycarbonate membranes allowing for easy coating of nanoparticle. However, if fabricated out of polydimethylsiloxane (PDMS), signal interference with the Raman spectrum can occur. PDMS generates a strong Raman signal which can easily overpower and interfere with the desired signal. A common solution for this is fabricating the microfluidic device such that a confocal pinhole can be used for the Raman laser. Typical confocal Raman microscopy allows for spectroscopic information from small focal volumes less than 1 micron cubed, and thus smaller than the microfluidic channel dimensions. Raman signal is inherently weak; therefore, for short detection times at small sample volumes in microfluidic devices, signal amplification is utilized.
=== Chemistry === Lonicera japonica leaves contain methyl caffeate, 3,4-di-O-caffeoylquinic acid, methyl 3,4-di-O-caffeoylquinic acid, protocatechuic acid, methyl chlorogenic acid, and luteolin. Other polyphenols present in the plant are hyperoside and caffeic acid. The two secoiridoid glycosides, loniceracetalides A and B, can be isolated, together with 10 known iridoid glycosides, from the flower buds.
Enhanced mobility – components are described as "familiar, performance-enhancing, eat-out-of-hand" foods that require little or no preparation by the soldier. The beverages are reconstituted (CamelBak compatible) and consumed right out of the pouch. No water is needed for food preparation, only for the beverage mix. The food takes the form of pocket sandwiches to be eaten by hand. Lightweight – when compared to three Meals, Ready-to-Eat, the FSR reduces the weight and volume of one day's subsistence by approximately 50%. Characteristics – has a minimum two-year shelf life at 80 °F (27 °C) and provides an average of 2,900 calories per day. The FSR has nine meals per shipping container consisting of three each of three different menus up through 2010. Since 2011 there are 9 different meal combinations per shipping container. Meals – Each pouch contains items for a breakfast, lunch, and a dinner, although there is no requirement to consume the items in any specific order.
Sources: en.wikipedia.org
== Atomic mass of isotopes == The atomic mass of an isotope (nuclide) is determined mainly by its atomic mass number (i.e. number of nucleons in its nucleus). Small corrections are due to the binding energy of the nucleus (see mass defect), the slight difference in mass between proton and neutron, and the mass of the electrons associated with the atom, the latter because the electron:nucleon ratio differs among isotopes. The mass number is a dimensionless quantity. The atomic mass, on the other hand, is measured using the dalton (symbol Da), which is defined in terms of the mass of the carbon-12 atom. It is also called the unified atomic mass unit (symbol u). The atomic masses of naturally occurring isotopes of an element determine the standard atomic weight of the element. When the element contains N isotopes, the expression below is applied for the average atomic mass
On March 19, 2012, UPS announced that it intended to acquire TNT Express for $6.8 billion, in a move to help expand its presence in European and Asian markets. However, the deal fell through in January 2013, after it was announced that UPS had failed to obtain permission from the European Commission and as such had been blocked on competition grounds. In February 2012, UPS acquired Brussels-based company Kiala that provides e-commerce retailers the option to have goods delivered to a conventional retail location. In 2018, The Wall Street Journal reported that UPS's operations were hampered by its outdated 20th-century technology, lagging behind its competitors. In May 2019, UPS launched a partnership with autonomous trucking startup TuSimple to carry cargo across Phoenix, Arizona, and Tucson, Arizona. In October 2019, UPS won the approval of the Federal Aviation Administration to fly drones. The certification will allow UPS to deliver health care supplies using a fleet of drones. On January 29, 2020, UPS announced it was investing in UK start-up Arrival and ordering 10,000 Generation 2 electric vehicles as a step towards a cleaner, more high-tech fleet. The deal ran from 2020 until 2024 and was reported to be worth more than $400 million. In March 2020, the company appointed Carol Tomé to succeed David Abney as its chief executive officer. It was viewed as a move to steer the parcel delivery company through the turbulence of trade wars, technological disruption and the risk of a pandemic-induced recession.
India Archived 11 January 2021 at the Wayback Machine. The World Factbook. Central Intelligence Agency. India web resources provided by GovPubs at the University of Colorado Boulder Libraries India from BBC News Wikimedia Atlas of India Geographic data related to India at OpenStreetMap Key Development Forecasts for India from International Futures
In March 2020, the Roche Diagnostics division reached a significant milestone with the FDA-approval of its high-volume Sars-CoV-2 diagnostic test, capable of analysing 1,400-8,800 samples within 24h on the proprietary Cobas 6800/8800 molecular testing system. In September, the business acquired Ireland-based Inflazome, for €380 million, gaining control of its NLRP3 inflammasome inhibitors. In March 2021, Roche announced it would acquire GenMark Diagnostics for $1.8 billion. Under the terms of agreement, Genmark diagnostics will become a subsidiary and the principal operations will continue to remain in Carlsbad, California. In September, the company announced it would acquire German biotech group, TIB Molbiol, enhancing its molecular diagnostics operations. In September 2022, Roche acquired Good Therapeutics at a cost of $250M for its PD1-regulated IL-2 receptor agonist program. In July 2023, Roche partnered with Alnylam Pharmaceuticals in a deal worth $2.8 billion for the development of a hypertension drug. In December 2023, Roche acquired Carmot Therapeutics, an anti-obesity drug developer, for $2.7 billion. In October 2023, Monte Rosa Therapeutics and Roche signed a strategic cooperation and licensing agreement for the discovery and development of molecular adhesive degradators (MGD) to combat cancer and neurological diseases. The partnership includes Monte Rosa's QuEENT discovery engine and Roche Holding expertise.
Sources: en.wikipedia.org
=== Glycoprotein IIb / IIIa complex (GPIIb / IIIa = integrin αIIbβ3) === This complex interacts with fibrinogen and thus plays an important role in platelet aggregation and adhesion to endothelial surfaces. Activation of this complex initiates the platelet aggregation and the formation of primary platelet plug, a fibrin clot. The IIb / IIIa complex is a major platelet membrane component. There are as many as 50 000 copies. The αIIb (GPIIb) is composed of two subunits linked by disulfide bridges. The β3 (GPIIIa) forms a single polypeptide chain. These subunits form Ca2+ - dependent complex on the surface of platelet membrane in a 1:1 ratio. Fibrinogen sites recognized by glycoprotein IIb / IIIa complex:
== Proliferative == Proliferative glomerulonephritis is characterised by an increased number of cells in the glomerulus. These forms usually present with a triad of blood in the urine, decreased urine production, and hypertension, the nephritic syndrome. These forms usually progress to end-stage kidney failure (ESKF) over weeks to years (depending on type).
== External links == "Remifentanil". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on June 28, 2019. "Remifentanil Hydrochloride". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on August 29, 2021.
Dalbavancin, sold under the brand names Dalvance in the US and Xydalba in the EU (both by AbbVie) among others, is a second-generation lipoglycopeptide antibiotic medication. It belongs to the same class as vancomycin, the most widely used and one of the treatments available to people infected with methicillin-resistant Staphylococcus aureus (MRSA). Dalbavancin is a semisynthetic lipoglycopeptide that was designed to improve upon the natural glycopeptides vancomycin and teicoplanin. It is derived from a complex of glycopeptide antibiotics, referred to as A-40926, that is produced by a new strain of Actinomadura. Dalbavancin has been referred to in the scientific literature by a series of names: MDL-63397, A-!-1, BI-397, VER-001. These different labels reflected where the research had been carried out: MDL representing Merrell-Dow-Lepetit, where the initial complex was discovered; BI referring to BioSearch Italia where Dalbavancin itself was first synthesized; VER referring to Versicor (which Biosearch Italia merged with to create Vicuron Pharmaceuticals). The phase I, II and III clinical trials were carried out of by Vicuron and the initial NDA filed. Vicuron was acquired by Pfizer in 2005, which decided to not further develop Dalbavancin at that time, subsequently selling the rights to Durata Therapeutics in 2009. It possesses in vitro activity against a variety of Gram-positive pathogens including MRSA and methicillin-resistant Staphylococcus epidermidis (MRSE).
== Further reading == Huang, T. C.; Teng, D. F. (2004). "Soy Sauce". Handbook of Food and Beverage Fermentation Technology. doi:10.1201/9780203913550.ch29 (inactive 12 July 2025). ISBN 978-0-8247-4780-0.{{cite book}}: CS1 maint: DOI inactive as of July 2025 (link)—on the production of soy sauce
Sources: en.wikipedia.org
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.
Sports authorities prohibit it because it is not approved for human use and has potential performance-enhancing effects. It appears on anti-doping lists under non-approved or metabolic modulator categories.
Detection usually uses liquid chromatography-tandem mass spectrometry. The method targets the parent compound or its metabolites in urine or blood.
Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.